Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.